|
|
||||||||
BRIEF REVIEWS |

* Cellular Biology and Viral Immunology Sections, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892; and
Departments of Pathology, and Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Thy-1 (CD90) is a small GPI-anchored protein that is particularly abundant on the surface of mouse thymocytes and peripheral T cells. T cell proliferation and cytokine synthesis in response to Thy-1 cross-linking by specific mAb suggests a role for Thy-1 in mouse T lymphocyte activation. However, a physiological ligand or counterreceptor for murine Thy-1 in the lymphoid compartment has not yet been identified. Thy-1 cross-linking, in the context of strong costimulatory signaling through CD28, results in an activating signal that can at least partially substitute for TCR signaling during mouse T cell activation. Remarkably, Thy-1 cross-linking also results in the potent costimulation of T cells activated through the TCR. This novel dual signaling capacity suggests a possible role for Thy-1 in the maintenance of T cell homeostasis in the absence of TCR triggering, as well as potentiating Ag-induced T cell responses.
This article has been cited by other articles:
![]() |
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu Dependence network modeling for biomarker identification Bioinformatics, January 15, 2007; 23(2): 198 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Rege and J. S. Hagood Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis FASEB J, June 1, 2006; 20(8): 1045 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ait-Azzouzene, L. Verkoczy, B. Duong, P. Skog, A. L. Gavin, and D. Nemazee Split Tolerance in Peripheral B Cell Subsets in Mice Expressing a Low Level of Ig{kappa}-Reactive Ligand J. Immunol., January 15, 2006; 176(2): 939 - 948. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |